Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 792 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... September 27, 2021 Quizartinib Approval Adds New Treatment Option for AML, Including in Older... August 15, 2023 How to Keep Your Loved One With Cancer Safe From Infection... December 22, 2022 FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... November 26, 2024 Load more HOT NEWS Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... Tratamiento agnóstico contra el cáncer: perspectiva de un experto New drug available for rare thyroid cancer on NHS in England Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome
